BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34196715)

  • 21. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
    Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
    Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
    Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
    Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
    Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
    BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
    Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):883-888. PubMed ID: 29976500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
    Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
    Nepple KG; Stephenson AJ; Kallogjeri D; Michalski J; Grubb RL; Strope SA; Haslag-Minoff J; Piccirillo JF; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Kibel AS
    Eur Urol; 2013 Sep; 64(3):372-8. PubMed ID: 23506834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
    Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE
    J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone.
    Andruska N; Fischer-Valuck BW; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Michalski JM; Baumann BC
    J Natl Compr Canc Netw; 2022 Feb; 20(4):343-350.e4. PubMed ID: 35193114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
    Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
    Gottschalk A
    Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.
    Miccio JA; Talcott WJ; Jairam V; Park HS; Yu JB; Leapman MS; Johnson SB; King MT; Nguyen PL; Kann BH
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):414-422. PubMed ID: 32989262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Prostate; 2022 Jan; 82(1):120-131. PubMed ID: 34662443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy.
    Guo Y; Mao S; Zhang A; Zhang J; Wang L; Wang R; Zhang W; Zhang Z; Wu Y; Cao X; Yang B; Yao X
    Front Oncol; 2019; 9():638. PubMed ID: 31380277
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.